Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brimonidine/Ketotifen Combo for Seasonal Allergic Conjunctivitis
NCT05591755Phase 3Completed
- Sponsor
- Bausch + Lomb
- Start
- Nov 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brimonidine and ketotifen in seasonal allergic conjunctivitis (SAC) (4 arms), sponsored by Bausch + Lomb. Primary endpoints: Ocular Itching Symptom Score and Ocular Redness Measured by Ocular Itching Scale. Started Nov 2022; status: completed.
02
Drugs
brimonidineketotifen
03
Conditions
seasonal allergic conjunctivitis (SAC)
Beyond the preview
Go deeper on NCT05591755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05591755.